REGENXBIO (RGNX) Financials

$9.76 -0.64 (-6.15%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$9.85 +0.09 (+0.92%)

As of 04:45 AM Eastern

Annual Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-280	-263	-227
Consolidated Net Income / (Loss)	-280	-263	-227
Net Income / (Loss) Continuing Operations	-280	-263	-227
Total Pre-Tax Income	-280	-264	-227
Total Operating Income	-263	-268	-233
Total Gross Profit	58	53	55
Total Revenue	113	90	83
Operating Revenue	113	90	83
Total Cost of Revenue	55	37	29
Operating Cost of Revenue	55	37	34
Other Cost of Revenue	0.00	0.00	-5.00
Total Operating Expenses	321	321	288
Selling, General & Admin Expense	85	88	77
Research & Development Expense	242	232	209
Other Operating Expenses / (Income)	-6.68	0.40	0.87
Impairment Charge	0.00	0.00	2.10
Total Other Income / (Expense), net	-18	4.48	6.24
Interest Expense	23	6.86	13
Interest & Investment Income	5.38	11	19
Other Income / (Expense), net	0.34	0.03	0.17
Income Tax Expense	-0.08	-0.15	0.00
Basic Earnings per Share	($6.50)	($6.02)	($4.59)
Weighted Average Basic Shares Outstanding	43.15M	43.73M	49.51M
Diluted Earnings per Share	($6.50)	($6.02)	($4.59)
Weighted Average Diluted Shares Outstanding	43.15M	43.73M	49.51M
Weighted Average Basic & Diluted Shares Outstanding	43.46M	44.43M	50.09M

This table shows REGENXBIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-75	-60	-67	-72	-62	-63	-63	-53	-60	-51
Consolidated Net Income / (Loss)	-75	-60	-67	-72	-62	-63	-63	-53	-60	-51
Net Income / (Loss) Continuing Operations	-75	-60	-67	-72	-62	-62	-63	-53	-60	-52
Total Pre-Tax Income	-75	-60	-67	-72	-62	-63	-63	-53	-60	-51
Total Operating Income	-71	-58	-66	-73	-65	-64	-64	-56	-62	-51
Total Gross Profit	13	19	15	11	17	11	11	12	12	20
Total Revenue	27	31	19	20	29	22	16	22	24	21
Operating Revenue	27	31	19	20	29	22	16	22	24	21
Total Cost of Revenue	13	13	4.11	9.48	12	11	4.28	11	12	1.32
Operating Cost of Revenue	13	13	4.11	9.48	12	11	4.28	11	12	6.32
Total Operating Expenses	84	76	81	84	81	75	75	68	74	71
Selling, General & Admin Expense	21	21	23	24	23	19	18	19	19	20
Research & Development Expense	63	63	59	60	58	56	55	49	54	50
Other Operating Expenses / (Income)	0.23	-7.38	0.03	0.03	0.22	0.12	-0.03	0.03	0.04	0.83
Total Other Income / (Expense), net	-4.44	-2.21	-0.52	1.05	3.09	0.86	0.53	3.05	2.48	0.18
Interest Expense	5.95	4.31	2.76	1.12	1.62	1.36	1.97	0.45	0.82	9.42
Interest & Investment Income	1.50	2.03	2.17	2.13	4.66	2.37	2.47	3.47	3.28	9.52
Other Income / (Expense), net	0.02	0.08	0.07	0.04	0.06	-0.14	0.04	0.03	0.03	0.08
Basic Earnings per Share	($1.75)	($1.38)	($1.53)	($1.66)	($1.41)	($1.42)	($1.38)	($1.05)	($1.17)	($0.99)
Weighted Average Basic Shares Outstanding	43.25M	43.15M	43.45M	43.53M	43.95M	43.73M	45.73M	50.60M	50.80M	49.51M
Diluted Earnings per Share	($1.75)	($1.38)	($1.53)	($1.66)	($1.41)	($1.42)	($1.38)	($1.05)	($1.17)	($0.99)
Weighted Average Diluted Shares Outstanding	43.25M	43.15M	43.45M	43.53M	43.95M	43.73M	45.73M	50.60M	50.80M	49.51M
Weighted Average Basic & Diluted Shares Outstanding	43.29M	43.46M	43.47M	43.96M	43.99M	44.43M	49.26M	49.42M	49.55M	50.09M

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-248	-62	23
Net Cash From Operating Activities	-207	-218	-173
Net Cash From Continuing Operating Activities	-207	-218	-173
Net Income / (Loss) Continuing Operations	-280	-263	-227
Consolidated Net Income / (Loss)	-280	-263	-227
Depreciation Expense	13	17	16
Amortization Expense	4.71	0.69	-4.14
Non-Cash Adjustments To Reconcile Net Income	45	37	34
Changes in Operating Assets and Liabilities, net	10	-10	7.42
Net Cash From Investing Activities	-12	191	103
Net Cash From Continuing Investing Activities	-12	191	103
Purchase of Property, Plant & Equipment	-31	-9.96	-2.44
Purchase of Investments	-185	-87	-190
Sale and/or Maturity of Investments	204	287	296
Net Cash From Financing Activities	-29	-35	93
Net Cash From Continuing Financing Activities	-29	-35	93
Issuance of Common Equity	1.74	6.70	132
Other Financing Activities, net	-31	-42	-40
Cash Income Taxes Paid	12	-0.14	-0.07

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-2.83	-22	-27	-1.27	-16	-19	78	-55	-1.15	0.91
Net Cash From Operating Activities	-50	-39	-81	-47	-49	-41	-55	-45	-41	-32
Net Cash From Continuing Operating Activities	-50	-39	-81	-47	-49	-41	-55	-45	-41	-32
Net Income / (Loss) Continuing Operations	-75	-60	-67	-72	-62	-63	-63	-53	-60	-51
Consolidated Net Income / (Loss)	-75	-60	-67	-72	-62	-63	-63	-53	-60	-51
Depreciation Expense	3.55	4.13	4.18	4.44	4.37	4.34	4.18	4.05	3.96	4.02
Amortization Expense	1.13	0.90	0.68	0.38	-0.13	-0.24	-0.47	-1.24	-1.32	-1.12
Non-Cash Adjustments To Reconcile Net Income	13	9.61	12	7.87	8.63	8.69	12	8.22	9.91	4.55
Changes in Operating Assets and Liabilities, net	6.96	5.93	-31	12	-0.40	9.34	-7.64	-3.54	6.49	12
Net Cash From Investing Activities	53	27	63	55	39	34	13	-0.27	50	40
Net Cash From Continuing Investing Activities	53	27	63	55	39	34	13	-0.27	50	40
Purchase of Property, Plant & Equipment	-5.05	-5.47	-4.82	-2.58	-1.44	-1.13	-0.56	-0.47	-0.33	-1.08
Purchase of Investments	-15	-12	0.00	-50	-18	-19	-55	-83	-36	-16
Sale and/or Maturity of Investments	73	44	68	108	58	54	69	83	87	58
Net Cash From Financing Activities	-5.42	-8.92	-9.04	-9.16	-4.81	-12	121	-9.45	-11	-7.74
Net Cash From Continuing Financing Activities	-5.42	-8.92	-9.04	-9.16	-4.81	-12	121	-9.45	-11	-7.74
Other Financing Activities, net	-6.54	-8.92	-9.62	-9.16	-11	-12	-11	-9.20	-11	-7.74

This table presents REGENXBIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	833	574	466
Total Current Assets	416	335	278
Cash & Equivalents	97	35	58
Short-Term Investments	268	241	177
Accounts Receivable	28	25	20
Prepaid Expenses	14	15	9.07
Other Current Assets	9.35	20	14
Plant, Property, & Equipment, net	142	132	118
Total Noncurrent Assets	276	107	70
Long-Term Investments	201	39	10
Noncurrent Note & Lease Receivables	1.50	0.70	0.47
Other Noncurrent Operating Assets	72	65	58
Other Noncurrent Nonoperating Assets	2.03	2.03	2.03
Total Liabilities & Shareholders' Equity	833	574	466
Total Liabilities	317	262	206
Total Current Liabilities	130	130	103
Accounts Payable	27	23	23
Accrued Expenses	47	50	38
Current Deferred Revenue	1.83	0.15	0.12
Other Current Liabilities	55	58	42
Total Noncurrent Liabilities	187	132	103
Other Noncurrent Operating Liabilities	187	132	103
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	516	312	260
Total Preferred & Common Equity	516	312	260
Preferred Stock	0.00	0.00	0.00
Total Common Equity	516	312	260
Common Stock	973	1,021	1,193
Retained Earnings	-442	-705	-932
Accumulated Other Comprehensive Income / (Loss)	-15	-4.43	-0.74

This table presents REGENXBIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	884	748	682	634	629	569	519
Total Current Assets	437	389	379	366	395	347	313
Cash & Equivalents	119	70	69	53	113	58	57
Short-Term Investments	264	262	251	249	226	233	199
Accounts Receivable	33	19	21	28	16	23	24
Prepaid Expenses	15	16	15	13	14	10	11
Other Current Assets	6.85	23	22	23	27	23	23
Plant, Property, & Equipment, net	141	142	139	136	128	124	121
Total Noncurrent Assets	306	217	165	132	106	99	85
Long-Term Investments	235	142	95	63	42	37	23
Noncurrent Note & Lease Receivables	1.80	1.30	1.14	1.08	0.52	0.46	0.40
Other Noncurrent Operating Assets	68	72	66	66	62	59	60
Other Noncurrent Nonoperating Assets	2.03	2.03	2.26	2.26	2.03	2.03	2.03
Total Liabilities & Shareholders' Equity	884	748	682	634	629	569	519
Total Liabilities	320	283	277	271	239	221	218
Total Current Liabilities	124	112	118	127	110	98	103
Accounts Payable	25	23	12	22	31	16	20
Accrued Expenses	44	32	51	46	33	42	49
Current Deferred Revenue	5.90	1.31	0.45	0.44	0.01	0.02	0.14
Other Current Liabilities	48	56	55	59	46	39	34
Total Noncurrent Liabilities	196	170	159	143	128	123	115
Other Noncurrent Operating Liabilities	196	170	159	143	128	123	115
Total Equity & Noncontrolling Interests	564	465	406	363	391	348	301
Total Preferred & Common Equity	564	465	406	363	391	348	301
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	564	465	406	363	391	348	301
Common Stock	964	985	996	1,013	1,162	1,172	1,183
Retained Earnings	-382	-508	-580	-642	-768	-821	-881
Accumulated Other Comprehensive Income / (Loss)	-18	-12	-10	-7.41	-3.23	-2.27	-0.58

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-76.03%	-19.94%	-7.66%
EBITDA Growth	-239.07%	-2.12%	11.59%
EBIT Growth	-263.37%	-2.12%	13.03%
NOPAT Growth	-227.09%	-2.00%	12.97%
Net Income Growth	-319.27%	6.00%	13.81%
EPS Growth	-323.37%	7.38%	23.75%
Operating Cash Flow Growth	-194.80%	-5.26%	20.73%
Free Cash Flow Firm Growth	-356.63%	-6.48%	22.96%
Invested Capital Growth	41.39%	91.35%	388.77%
Revenue Q/Q Growth	-75.56%	-9.19%	-1.18%
EBITDA Q/Q Growth	-286.16%	-3.00%	4.97%
EBIT Q/Q Growth	-328.50%	-2.43%	5.19%
NOPAT Q/Q Growth	-300.39%	-2.34%	5.10%
Net Income Q/Q Growth	-480.68%	-1.13%	4.90%
EPS Q/Q Growth	-477.91%	-0.67%	8.57%
Operating Cash Flow Q/Q Growth	-219.67%	-0.64%	5.01%
Free Cash Flow Firm Q/Q Growth	-398.86%	0.27%	8.19%
Invested Capital Q/Q Growth	7.57%	-19.99%	-38.73%
Profitability Metrics	-	-	-
Gross Margin	51.61%	58.76%	65.72%
EBITDA Margin	-217.27%	-277.14%	-265.34%
Operating Margin	-233.20%	-297.12%	-280.03%
EBIT Margin	-232.90%	-297.09%	-279.82%
Profit (Net Income) Margin	-248.68%	-291.99%	-272.54%
Tax Burden Percent	99.97%	99.94%	100.00%
Interest Burden Percent	106.81%	98.34%	97.40%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-3,918.02%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-3,895.37%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	3,838.53%
Return on Equity (ROE)	-43.78%	-63.65%	-79.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,415.24%
Operating Return on Assets (OROA)	-26.97%	-38.10%	-44.84%
Return on Assets (ROA)	-28.79%	-37.45%	-43.68%
Return on Common Equity (ROCE)	-43.78%	-63.65%	-79.49%
Return on Equity Simple (ROE_SIMPLE)	-54.31%	-84.52%	-87.46%
Net Operating Profit after Tax (NOPAT)	-184	-188	-163
NOPAT Margin	-163.24%	-207.98%	-196.02%
Net Nonoperating Expense Percent (NNEP)	-13.58%	-17.16%	-22.65%
Return On Investment Capital (ROIC_SIMPLE)	-35.65%	-60.21%	-62.91%
Cost of Revenue to Revenue	48.39%	41.24%	34.28%
SG&A Expenses to Revenue	75.65%	98.06%	91.95%
R&D to Revenue	215.09%	257.38%	250.24%
Operating Expenses to Revenue	284.82%	355.88%	345.75%
Earnings before Interest and Taxes (EBIT)	-263	-268	-233
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-245	-250	-221
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.90	2.53	1.48
Price to Tangible Book Value (P/TBV)	1.90	2.53	1.48
Price to Revenue (P/Rev)	8.71	8.75	4.60
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	10.83
Enterprise Value to Revenue (EV/Rev)	3.70	5.27	1.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.11	-1.07	-0.99
Leverage Ratio	1.52	1.70	1.82
Compound Leverage Factor	1.62	1.67	1.77
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.62	-0.87	-2.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.19	2.57	2.69
Quick Ratio	3.01	2.30	2.47
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-220	-234	-181
Operating Cash Flow to CapEx	-675.33%	-2,192.84%	-7,106.94%
Free Cash Flow to Firm to Interest Expense	-9.46	-34.15	-14.26
Operating Cash Flow to Interest Expense	-8.92	-31.83	-13.68
Operating Cash Flow Less CapEx to Interest Expense	-10.24	-33.28	-13.87
Efficiency Ratios	-	-	-
Asset Turnover	0.12	0.13	0.16
Accounts Receivable Turnover	3.73	3.41	3.68
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.83	0.66	0.67
Accounts Payable Turnover	2.83	1.49	1.25
Days Sales Outstanding (DSO)	97.98	106.93	99.13
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	129.15	245.21	291.21
Cash Conversion Cycle (CCC)	-31.17	-138.28	-192.08
Capital & Investment Metrics	-	-	-
Invested Capital	-51	-4.42	13
Invested Capital Turnover	-1.63	-3.25	19.99
Increase / (Decrease) in Invested Capital	36	47	17
Enterprise Value (EV)	417	476	138
Market Capitalization	982	790	383
Book Value per Share	$11.92	$7.09	$5.24
Tangible Book Value per Share	$11.92	$7.09	$5.24
Total Capital	516	312	260
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-565	-314	-245
Capital Expenditures (CapEx)	31	9.96	2.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-79	-71	-60
Debt-free Net Working Capital (DFNWC)	286	205	175
Net Working Capital (NWC)	286	205	175
Net Nonoperating Expense (NNE)	96	76	64
Net Nonoperating Obligations (NNO)	-567	-316	-247
Total Depreciation and Amortization (D&A)	18	18	12
Debt-free, Cash-free Net Working Capital to Revenue	-70.17%	-78.19%	-71.86%
Debt-free Net Working Capital to Revenue	253.31%	226.83%	209.78%
Net Working Capital to Revenue	253.31%	226.83%	209.78%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($6.50)	($6.02)	($4.59)
Adjusted Weighted Average Basic Shares Outstanding	43.15M	43.73M	49.51M
Adjusted Diluted Earnings per Share	($6.50)	($6.02)	($4.59)
Adjusted Weighted Average Diluted Shares Outstanding	43.15M	43.73M	49.51M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	43.46M	44.43M	50.09M
Normalized Net Operating Profit after Tax (NOPAT)	-184	-188	-162
Normalized NOPAT Margin	-163.24%	-207.98%	-194.26%
Pre Tax Income Margin	-248.75%	-292.15%	-272.54%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-11.29	-39.07	-18.42
NOPAT to Interest Expense	-7.91	-27.35	-12.90
EBIT Less CapEx to Interest Expense	-12.61	-40.52	-18.61
NOPAT Less CapEx to Interest Expense	-9.23	-28.80	-13.10
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-13.85%	-91.75%	-13.86%	-38.81%	9.06%	-29.13%	-18.37%	11.60%	-16.31%	-4.50%
EBITDA Growth	-25.43%	-116.26%	9.13%	-16.63%	8.56%	-13.83%	1.82%	22.05%	2.07%	19.30%
EBIT Growth	-24.11%	-118.04%	7.48%	-17.13%	8.62%	-11.01%	3.42%	23.35%	4.39%	19.92%
NOPAT Growth	-23.88%	-113.48%	7.51%	-16.91%	8.57%	-10.61%	3.47%	23.35%	4.44%	19.62%
Net Income Growth	-29.24%	-120.38%	13.10%	-5.69%	18.04%	-4.93%	5.02%	26.47%	3.67%	18.61%
EPS Growth	-27.74%	-120.18%	14.53%	-5.06%	19.43%	-2.90%	9.80%	36.75%	17.02%	30.28%
Operating Cash Flow Growth	-18.71%	-111.53%	-44.73%	23.36%	2.08%	-3.53%	31.47%	3.86%	17.93%	22.41%
Free Cash Flow Firm Growth	-143.05%	-131.75%	-48.32%	95.54%	-42.81%	-19.44%	44.05%	-862.71%	29.95%	41.84%
Invested Capital Growth	24.79%	41.39%	86.50%	-136.68%	93.33%	91.35%	178.01%	260.70%	665.55%	388.77%
Revenue Q/Q Growth	-18.80%	18.23%	-38.94%	4.38%	44.74%	-23.18%	-29.67%	42.72%	8.53%	-12.33%
EBITDA Q/Q Growth	-13.38%	20.62%	-16.26%	-11.48%	11.12%	1.18%	-0.27%	11.50%	-11.67%	18.56%
EBIT Q/Q Growth	-13.86%	18.77%	-14.55%	-10.56%	11.17%	1.33%	0.34%	12.25%	-10.79%	17.35%
NOPAT Q/Q Growth	-13.61%	18.68%	-14.52%	-10.51%	11.15%	1.63%	0.06%	12.25%	-10.78%	17.25%
Net Income Q/Q Growth	-10.71%	20.60%	-11.25%	-8.08%	14.15%	-1.65%	-0.70%	16.33%	-12.47%	14.11%
EPS Q/Q Growth	-10.76%	21.14%	-10.87%	-8.50%	15.06%	-0.71%	2.82%	23.91%	-11.43%	15.38%
Operating Cash Flow Q/Q Growth	18.29%	21.97%	-105.52%	41.52%	-4.41%	17.50%	-36.05%	17.96%	10.88%	22.01%
Free Cash Flow Firm Q/Q Growth	58.31%	-12.59%	-47.81%	93.57%	-1,235.18%	5.83%	30.77%	-10.59%	2.85%	21.81%
Invested Capital Q/Q Growth	-271.88%	7.57%	79.59%	-13.12%	68.76%	-19.99%	283.97%	133.04%	9.93%	-38.73%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.61%	59.22%	78.51%	52.57%	57.16%	49.41%	72.58%	52.55%	48.81%	93.79%
EBITDA Margin	-250.25%	-168.02%	-319.92%	-341.66%	-209.81%	-269.89%	-384.80%	-238.62%	-245.52%	-228.05%
Operating Margin	-267.97%	-184.31%	-345.68%	-365.96%	-224.67%	-287.68%	-408.80%	-251.34%	-256.55%	-242.14%
EBIT Margin	-267.91%	-184.06%	-345.32%	-365.76%	-224.47%	-288.32%	-408.56%	-251.21%	-256.45%	-241.75%
Profit (Net Income) Margin	-284.72%	-191.21%	-348.40%	-360.72%	-213.97%	-283.12%	-405.39%	-237.67%	-246.30%	-241.28%
Tax Burden Percent	100.00%	99.93%	100.00%	100.00%	100.00%	99.76%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	106.28%	103.96%	100.89%	98.62%	95.32%	98.43%	99.22%	94.61%	96.04%	99.81%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-2,442.39%	0.00%	0.00%	0.00%	-4,380.38%	-1,767.41%	-3,387.87%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-2,438.28%	0.00%	0.00%	0.00%	-4,376.70%	-1,762.42%	-3,382.46%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	2,390.42%	0.00%	0.00%	0.00%	4,335.18%	1,716.97%	3,333.11%
Return on Equity (ROE)	14.36%	-43.78%	-46.81%	-51.97%	-56.22%	-63.65%	-60.80%	-45.20%	-50.44%	-54.77%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,518.17%	-1,081.77%	-944.45%	-1,415.24%
Operating Return on Assets (OROA)	-146.71%	-21.31%	-42.70%	-43.36%	-29.40%	-36.98%	-51.46%	-35.74%	-37.52%	-38.74%
Return on Assets (ROA)	-155.92%	-22.14%	-43.09%	-42.77%	-28.02%	-36.31%	-51.06%	-33.81%	-36.03%	-38.67%
Return on Common Equity (ROCE)	14.36%	-43.78%	-46.81%	-51.97%	-56.22%	-63.65%	-60.80%	-45.20%	-50.44%	-54.77%
Return on Equity Simple (ROE_SIMPLE)	13.06%	0.00%	-58.11%	-67.55%	-71.75%	0.00%	-66.59%	-69.22%	-79.23%	0.00%
Net Operating Profit after Tax (NOPAT)	-50	-40	-46	-51	-45	-45	-45	-39	-43	-36
NOPAT Margin	-187.58%	-129.01%	-241.98%	-256.17%	-157.27%	-201.38%	-286.16%	-175.94%	-179.59%	-169.50%
Net Nonoperating Expense Percent (NNEP)	-4.46%	-2.75%	-3.28%	-4.11%	-3.33%	-4.11%	-4.34%	-3.69%	-4.99%	-5.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.83%	-	-	-	-14.35%	-	-	-	-13.85%
Cost of Revenue to Revenue	49.39%	40.78%	21.49%	47.43%	42.84%	50.59%	27.42%	47.45%	51.19%	6.21%
SG&A Expenses to Revenue	78.91%	67.67%	118.27%	118.63%	79.83%	85.89%	117.08%	84.57%	80.27%	94.52%
R&D to Revenue	238.81%	199.41%	305.76%	299.77%	201.23%	250.67%	351.07%	219.19%	224.94%	237.48%
Operating Expenses to Revenue	318.58%	243.53%	424.20%	418.53%	281.82%	337.09%	481.39%	303.89%	305.36%	335.93%
Earnings before Interest and Taxes (EBIT)	-71	-58	-66	-73	-65	-64	-64	-56	-62	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-66	-53	-61	-68	-61	-60	-60	-53	-59	-48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.03	1.90	1.77	2.14	1.99	2.53	2.37	1.65	1.72	1.48
Price to Tangible Book Value (P/TBV)	2.03	1.90	1.77	2.14	1.99	2.53	2.37	1.65	1.72	1.48
Price to Revenue (P/Rev)	2.48	8.71	7.50	8.96	7.28	8.75	10.69	6.47	6.15	4.60
Price to Earnings (P/E)	9.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	10.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	67.24	13.15	11.52	10.83
Enterprise Value to Revenue (EV/Rev)	1.14	3.70	3.18	4.68	3.61	5.27	6.30	2.80	2.84	1.66
Enterprise Value to EBITDA (EV/EBITDA)	3.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	4.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	3.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	7.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.13	-1.11	-1.08	-0.98	-1.06	-1.07	-1.00	-0.99	-0.97	-0.99
Leverage Ratio	1.64	1.52	1.54	1.58	1.64	1.70	1.61	1.66	1.73	1.82
Compound Leverage Factor	1.75	1.58	1.55	1.56	1.56	1.67	1.60	1.57	1.67	1.82
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.22	1.43	1.09	0.94	0.46	0.30	0.97	-0.10	-0.69	-1.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.53	3.19	3.46	3.21	2.87	2.57	3.59	3.53	3.05	2.69
Quick Ratio	3.36	3.01	3.12	2.90	2.59	2.30	3.22	3.19	2.72	2.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-68	-76	-113	-7.27	-97	-91	-63	-70	-68	-53
Operating Cash Flow to CapEx	-999.13%	-719.78%	-1,679.49%	-1,836.32%	-3,433.43%	-3,619.89%	-9,956.01%	-9,598.52%	-12,438.34%	-2,930.86%
Free Cash Flow to Firm to Interest Expense	-11.41	-17.74	-41.03	-6.49	-59.73	-67.02	-32.06	-155.78	-82.87	-5.64
Operating Cash Flow to Interest Expense	-8.47	-9.14	-29.37	-42.25	-30.42	-29.90	-28.11	-101.33	-49.45	-3.36
Operating Cash Flow Less CapEx to Interest Expense	-9.32	-10.40	-31.12	-44.55	-31.31	-30.73	-28.39	-102.39	-49.85	-3.47
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.55	0.12	0.12	0.12	0.13	0.13	0.13	0.14	0.15	0.16
Accounts Receivable Turnover	11.74	3.73	4.78	3.29	3.28	3.41	5.00	4.03	3.27	3.68
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	3.51	0.83	0.79	0.70	0.72	0.66	0.64	0.68	0.66	0.67
Accounts Payable Turnover	2.76	2.83	1.79	2.76	1.65	1.49	1.37	2.75	1.86	1.25
Days Sales Outstanding (DSO)	31.09	97.98	76.37	110.81	111.28	106.93	73.00	90.57	111.77	99.13
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	132.09	129.15	203.97	132.37	221.63	245.21	266.73	132.77	196.22	291.21
Cash Conversion Cycle (CCC)	-100.99	-31.17	-127.60	-21.56	-110.36	-138.28	-193.74	-42.21	-84.45	-192.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-55	-51	-10	-12	-3.68	-4.42	8.13	19	21	13
Invested Capital Turnover	-7.17	-1.63	-2.50	9.53	-3.37	-3.25	-75.71	24.90	9.84	19.99
Increase / (Decrease) in Invested Capital	18	36	67	-44	52	47	19	31	24	17
Enterprise Value (EV)	526	417	348	454	359	476	546	249	240	138
Market Capitalization	1,143	982	822	869	724	790	927	576	518	383
Book Value per Share	$13.04	$11.92	$10.70	$9.34	$8.26	$7.09	$8.54	$7.07	$6.10	$5.24
Tangible Book Value per Share	$13.04	$11.92	$10.70	$9.34	$8.26	$7.09	$8.54	$7.07	$6.10	$5.24
Total Capital	564	516	465	406	363	312	391	348	301	260
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-617	-565	-474	-415	-365	-314	-381	-327	-279	-245
Capital Expenditures (CapEx)	5.05	5.47	4.82	2.58	1.44	1.13	0.56	0.47	0.33	1.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-69	-79	-55	-59	-63	-71	-53	-42	-45	-60
Debt-free Net Working Capital (DFNWC)	313	286	277	261	238	205	285	248	211	175
Net Working Capital (NWC)	313	286	277	261	238	205	285	248	211	175
Net Nonoperating Expense (NNE)	26	19	20	21	16	18	19	14	16	15
Net Nonoperating Obligations (NNO)	-619	-567	-476	-418	-367	-316	-383	-329	-281	-247
Total Depreciation and Amortization (D&A)	4.68	5.03	4.86	4.82	4.24	4.09	3.71	2.81	2.65	2.91
Debt-free, Cash-free Net Working Capital to Revenue	-15.03%	-70.17%	-50.12%	-61.01%	-63.79%	-78.19%	-61.65%	-47.11%	-53.11%	-71.86%
Debt-free Net Working Capital to Revenue	67.89%	253.31%	252.52%	269.06%	239.99%	226.83%	328.90%	278.97%	249.83%	209.78%
Net Working Capital to Revenue	67.89%	253.31%	252.52%	269.06%	239.99%	226.83%	328.90%	278.97%	249.83%	209.78%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.75)	($1.38)	($1.53)	($1.66)	($1.41)	($1.42)	($1.38)	($1.05)	($1.17)	($0.99)
Adjusted Weighted Average Basic Shares Outstanding	43.25M	43.15M	43.45M	43.53M	43.95M	43.73M	45.73M	50.60M	50.80M	49.51M
Adjusted Diluted Earnings per Share	($1.75)	($1.38)	($1.53)	($1.66)	($1.41)	($1.42)	($1.38)	($1.05)	($1.17)	($0.99)
Adjusted Weighted Average Diluted Shares Outstanding	43.25M	43.15M	43.45M	43.53M	43.95M	43.73M	45.73M	50.60M	50.80M	49.51M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	43.29M	43.46M	43.47M	43.96M	43.99M	44.43M	49.26M	49.42M	49.55M	50.09M
Normalized Net Operating Profit after Tax (NOPAT)	-50	-40	-46	-51	-45	-45	-43	-39	-43	-36
Normalized NOPAT Margin	-187.58%	-129.01%	-241.98%	-256.17%	-157.27%	-201.38%	-276.75%	-175.94%	-179.59%	-169.50%
Pre Tax Income Margin	-284.72%	-191.35%	-348.40%	-360.72%	-213.97%	-283.80%	-405.39%	-237.67%	-246.30%	-241.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.93	-13.39	-23.99	-65.24	-39.97	-46.99	-32.35	-124.74	-75.67	-5.45
NOPAT to Interest Expense	-8.35	-9.38	-16.81	-45.69	-28.00	-32.82	-22.66	-87.36	-52.99	-3.82
EBIT Less CapEx to Interest Expense	-12.78	-14.66	-25.74	-67.54	-40.85	-47.81	-32.63	-125.80	-76.07	-5.56
NOPAT Less CapEx to Interest Expense	-9.20	-10.65	-18.56	-47.99	-28.89	-33.65	-22.94	-88.42	-53.39	-3.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.10%	0.00%	0.00%

Frequently Asked Questions About REGENXBIO's Financials

When does REGENXBIO's fiscal year end?

According to the most recent income statement we have on file, REGENXBIO's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has REGENXBIO's net income changed over the last 2 years?

REGENXBIO's net income appears to be on a downward trend, with a most recent value of -$227.10 million in 2024, falling from -$280.32 million in 2022. The previous period was -$263.49 million in 2023. See REGENXBIO's forecast for analyst expectations on what’s next for the company.

What is REGENXBIO's operating income?

REGENXBIO's total operating income in 2024 was -$233.35 million, based on the following breakdown:

Total Gross Profit: $54.76 million
Total Operating Expenses: $288.11 million

How has REGENXBIO revenue changed over the last 2 years?

Over the last 2 years, REGENXBIO's total revenue changed from $112.72 million in 2022 to $83.33 million in 2024, a change of -26.1%.

How much debt does REGENXBIO have?

REGENXBIO's total liabilities were at $206.34 million at the end of 2024, a 21.3% decrease from 2023, and a 34.9% decrease since 2022.

How much cash does REGENXBIO have?

In the past 2 years, REGENXBIO's cash and equivalents has ranged from $34.52 million in 2023 to $96.95 million in 2022, and is currently $57.53 million as of their latest financial filing in 2024.

How has REGENXBIO's book value per share changed over the last 2 years?

Over the last 2 years, REGENXBIO's book value per share changed from 11.92 in 2022 to 5.24 in 2024, a change of -56.0%.

Related Companies

This page (NASDAQ:RGNX) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Financials

Frequently Asked Questions About REGENXBIO's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Financials

Annual Income Statements for REGENXBIO

Quarterly Income Statements for REGENXBIO

Annual Cash Flow Statements for REGENXBIO

Quarterly Cash Flow Statements for REGENXBIO

Annual Balance Sheets for REGENXBIO

Quarterly Balance Sheets for REGENXBIO

Annual Metrics and Ratios for REGENXBIO

Quarterly Metrics and Ratios for REGENXBIO

Frequently Asked Questions About REGENXBIO's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools